Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04783415
Title Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors City of Hope Medical Center

mantle cell lymphoma


Acalabrutinib + Ublituximab + Umbralisib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST